{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:30:59Z","timestamp":1789428659174,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006264","name":"RIKEN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008273","name":"Novartis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004031","name":"Jichi Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003887","name":"International Myeloma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008667","name":"SENSHIN Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008670","name":"Terumo Foundation for Life Sciences and Arts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.bneo.2025.100091","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:23:43Z","timestamp":1741699423000},"page":"100091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Discovery of a novel class NSD2 inhibitor for multiple myeloma with t(4;14)+"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3697-6020","authenticated-orcid":false,"given":"Sae","family":"Matsuoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Osada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Kikuzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4134-4286","authenticated-orcid":false,"given":"Hiroo","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4257-9151","authenticated-orcid":false,"given":"Akiko","family":"Idei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4376-5674","authenticated-orcid":false,"given":"Minoru","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5651-1182","authenticated-orcid":false,"given":"Masaki","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3464-2960","authenticated-orcid":false,"given":"Takashi","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0742-3896","authenticated-orcid":false,"given":"Chiduru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3761-9504","authenticated-orcid":false,"given":"Teruki","family":"Honma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0905-6855","authenticated-orcid":false,"given":"Hiroshi","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3787","authenticated-orcid":false,"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakasone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8791-3263","authenticated-orcid":false,"given":"Jiro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7249-6418","authenticated-orcid":false,"given":"Yusuke","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bneo.2025.100091_bib1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7835","key":"10.1016\/j.bneo.2025.100091_bib2","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1038\/d41586-020-03223-2","article-title":"Outlook: multiple myeloma","volume":"587","author":"Owens","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bneo.2025.100091_bib3","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12185-020-02841-w","article-title":"Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost","volume":"111","author":"Suzuki","year":"2020","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100091_bib4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s12185-020-02829-6","article-title":"Molecular basis of clonal evolution in multiple myeloma","volume":"111","author":"Furukawa","year":"2020","journal-title":"Int J Hematol"},{"issue":"26","key":"10.1016\/j.bneo.2025.100091_bib5","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.bneo.2025.100091_bib6","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project","volume":"40","author":"Cairns","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100091_bib7","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial","volume":"34","author":"Pawlyn","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2025.100091_bib8","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100091_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/bjh.17499","article-title":"Subgroup analysis of ICARIA-MM study in relapsed\/refractory multiple myeloma patients with high-risk cytogenetics","volume":"194","author":"Harrison","year":"2021","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.bneo.2025.100091_bib10","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.3324\/haematol.2022.280660","article-title":"Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed\/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA","volume":"107","author":"Martin","year":"2022","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bneo.2025.100091_bib11","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.18632\/oncotarget.1049","article-title":"Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in t(4;14) multiple myeloma","volume":"4","author":"Xie","year":"2013","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.bneo.2025.100091_bib12","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/leu.2015.169","article-title":"MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib","volume":"29","author":"Xie","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2025.100091_bib13","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/636514","article-title":"MMSET: role and therapeutic opportunities in multiple myeloma","volume":"2014","author":"Xie","year":"2014","journal-title":"BioMed Res Int"},{"issue":"2","key":"10.1016\/j.bneo.2025.100091_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2024.100151","article-title":"NSD family proteins: rising stars as therapeutic targets","volume":"3","author":"He","year":"2024","journal-title":"Cell Insight"},{"issue":"15","key":"10.1016\/j.bneo.2025.100091_bib15","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/cmdc.201800233","article-title":"Development of novel inhibitors for histone methyltransferase SET7\/9 based on cyproheptadine","volume":"13","author":"Hirano","year":"2018","journal-title":"Chem Med Chem"},{"issue":"8","key":"10.1016\/j.bneo.2025.100091_bib16","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1021\/acs.jmedchem.5b01732","article-title":"Identification of cyproheptadine as an inhibitor of SET domain containing lysine methyltransferase 7\/9 (Set7\/9) that regulates estrogen-dependent transcription","volume":"59","author":"Takemoto","year":"2016","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bneo.2025.100091_bib17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2010-07-298349","article-title":"The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells","volume":"117","author":"Martinez-Garcia","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2025.100091_bib18","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1158\/1078-0432.CCR-18-0919","article-title":"Eradication of central nervous system leukemia of T-cell origin with a brain-permeable LSD1 inhibitor","volume":"25","author":"Saito","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.bneo.2025.100091_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1364","article-title":"c-FOS mediates IMiDs resistance acting as a co-activator of IKZF1-target genes in multiple myeloma","volume":"13","author":"Osada","year":"2023","journal-title":"Clin Transl Med"},{"issue":"12","key":"10.1016\/j.bneo.2025.100091_bib20","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1172\/JCI80325","article-title":"Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma","volume":"125","author":"Kikuchi","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bneo.2025.100091_bib21","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.3324\/haematol.2021.278506","article-title":"mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation","volume":"106","author":"Osada","year":"2021","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.bneo.2025.100091_bib22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/bjc.1967.32","article-title":"A trial of streptonigrin in the treatment of advanced malignant disease","volume":"21","author":"Smith","year":"1967","journal-title":"Br J Cancer"},{"issue":"35","key":"10.1016\/j.bneo.2025.100091_bib23","doi-asserted-by":"crossref","first-page":"13750","DOI":"10.1074\/jbc.RA118.004274","article-title":"High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2","volume":"293","author":"Coussens","year":"2018","journal-title":"J Biol Chem"},{"issue":"5A","key":"10.1016\/j.bneo.2025.100091_bib24","first-page":"3067","article-title":"Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284)","volume":"27","author":"Guo","year":"2007","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.bneo.2025.100091_bib25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/leu.2013.204","article-title":"Point mutation E1099K in MMSET\/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies","volume":"28","author":"Oyer","year":"2014","journal-title":"Leukemia"},{"issue":"7201","key":"10.1016\/j.bneo.2025.100091_bib26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bneo.2025.100091_bib27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.stem.2020.12.017","article-title":"Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption","volume":"28","author":"Mondala","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"5","key":"10.1016\/j.bneo.2025.100091_bib28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrg3173","article-title":"Histone methylation: a dynamic mark in health, disease and inheritance","volume":"13","author":"Greer","year":"2012","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.bneo.2025.100091_bib29","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1038\/s41467-019-12811-4","article-title":"NSD2 overexpression drives clustered chromatin and transcriptional changes in a subset of insulated domains","volume":"10","author":"Lhoumaud","year":"2019","journal-title":"Nat Commun"},{"issue":"16","key":"10.1016\/j.bneo.2025.100091_bib30","doi-asserted-by":"crossref","first-page":"10991","DOI":"10.1021\/acs.jmedchem.3c00948","article-title":"Drug discovery targeting nuclear receptor binding SET domain protein 2 (NSD2)","volume":"66","author":"Ma","year":"2023","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.bneo.2025.100091_bib31","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1158\/1078-0432.CCR-10-1302","article-title":"The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors","volume":"17","author":"Hudlebusch","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bneo.2025.100091_bib32","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1172\/JCI91144","article-title":"AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis","volume":"127","author":"Li","year":"2017","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.bneo.2025.100091_bib33","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/jso.23234","article-title":"Overexpression of MMSET may contribute to the progression of endometrial cancer and also may serve as a new biomarker to predict the prognosis of endometrial cancer","volume":"107","author":"Xiao","year":"2013","journal-title":"J Surg Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100091_bib34","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.mehy.2004.03.031","article-title":"S-adenosylhomocysteine hydrolase, S-adenosylmethionine, S-adenosylhomocysteine: correlations with ribavirin induced anemia","volume":"63","author":"Altintas","year":"2004","journal-title":"Med Hypotheses"},{"issue":"24","key":"10.1016\/j.bneo.2025.100091_bib35","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1016\/0006-2952(86)90774-4","article-title":"3-Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells","volume":"35","author":"Glazer","year":"1986","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100091_bib36","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/1535-7163.MCT-09-0013","article-title":"DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation","volume":"8","author":"Miranda","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.bneo.2025.100091_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.15430\/JCP.2015.20.2.113","article-title":"Inhibition of nuclear receptor binding SET domain 2\/multiple myeloma SET domain by LEM-06 implication for epigenetic cancer therapies","volume":"20","author":"di Luccio","year":"2015","journal-title":"J Cancer Prevent"},{"key":"10.1016\/j.bneo.2025.100091_bib38","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1007\/s00044-017-1909-7","article-title":"BIX-01294 inhibits oncoproteins NSD1, NSD2 and NSD3","volume":"26","author":"Morishita","year":"2017","journal-title":"Med Chem Res"},{"issue":"11","key":"10.1016\/j.bneo.2025.100091_bib39","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1021\/acschembio.6b00308","article-title":"Structure of the epigenetic oncogene MMSET and inhibition by N-alkyl sinefungin derivatives","volume":"11","author":"Tisi","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bneo.2025.100091_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113592","article-title":"5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma","volume":"222","author":"Wang","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"19","key":"10.1016\/j.bneo.2025.100091_bib41","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1158\/0008-5472.CAN-20-2946","article-title":"SMARCA2 is a novel interactor of NSD2 and regulates prometastatic PTP4A3 through chromatin remodeling in t(4;14) multiple myeloma","volume":"81","author":"Chong","year":"2021","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.bneo.2025.100091_bib42","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1021\/acs.jmedchem.0c01768","article-title":"Discovery of small-molecule antagonists of the PWWP domain of NSD2","volume":"64","author":"Ferreira de Freitas","year":"2021","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bneo.2025.100091_bib43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41589-021-00898-0","article-title":"A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization","volume":"18","author":"Dilworth","year":"2022","journal-title":"Nat Chem Biol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T02:59:31Z","timestamp":1762657171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2950328025000263"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100091","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a novel class NSD2 inhibitor for multiple myeloma with t(4;14)+","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100091"}}